A - NYSE
Agilent Technologies, Inc.
$137.40
+0.99%Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
At a Glance
Live SnapshotAgilent Technologies, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Healthy operating margins demonstrate effective cost control and strong business fundamentals.
Net Profit Margin
Strong net margins indicate efficient operations and favorable tax/interest management.
Effective Tax Rate
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Profitability Insight
Exceptional profitability across all levels: Strong pricing power, efficient operations, and healthy bottom line indicate a high-quality business with sustainable competitive advantages.
Agilent Technologies, Inc. Income Statement
A • NYSE
| Agilent Technologies, Inc. Income Statement | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 | Oct 2020 | Oct 2019 | Oct 2018 | Oct 2017 | Oct 2016 | Oct 2015 | Oct 2014 | Oct 2013 | Oct 2012 | Oct 2011 | Oct 2010 | Oct 2009 | Oct 2008 | Oct 2007 | Oct 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
6.9B | 6.5B | 6.8B | 6.8B | 6.3B | 5.3B | 5.2B | 4.9B | 4.5B | 4.2B | 4B | 4B | 3.9B | 6.9B | 6.6B | 5.4B | 4.5B | 5.8B | 5.4B | 5B | |
GROSS PROFIT | ||||||||||||||||||||
(3.3B) | (3B) | (3.4B) | (3.1B) | (2.9B) | (2.5B) | (2.4B) | (2.2B) | (2.1B) | (2B) | (2B) | (2.1B) | (2B) | (3.3B) | (3.1B) | (2.5B) | (2.2B) | (2.6B) | (2.5B) | (2.3B) | |
3.6B | 3.5B | 3.5B | 3.7B | 3.4B | 2.8B | 2.8B | 2.7B | 2.4B | 2.2B | 2B | 2B | 1.9B | 3.6B | 3.5B | 2.9B | 2.3B | 3.2B | 3B | 2.7B | |
OPERATING INCOME | ||||||||||||||||||||
(2.2B) | (2B) | (2.1B) | (2.1B) | (2.1B) | (2B) | (1.9B) | (1.8B) | (1.6B) | (1.6B) | (1.5B) | (1.6B) | (1.5B) | (2.5B) | (2.5B) | (2.4B) | (2.2B) | (2.4B) | (2.4B) | (2.2B) | |
(1.7B) | (1.5B) | (1.6B) | (1.6B) | (1.6B) | (1.5B) | (1.5B) | (1.4B) | (1.2B) | (1.3B) | (1.2B) | (2B) | (1.9B) | (1.8B) | (1.8B) | (1.8B) | (1.6B) | (1.7B) | (1.7B) | (1.7B) | |
(455M) | (479M) | (481M) | (467M) | (441M) | (495M) | (404M) | (385M) | (339M) | (329M) | (330M) | (719M) | (704M) | (668M) | (649M) | (612M) | (642M) | (704M) | (685M) | (655M) | |
1.5B | 1.5B | 1.4B | 1.6B | 1.3B | 846M | 941M | 904M | 841M | 615M | 522M | 419M | 386M | 1.1B | 1.1B | 566M | 47M | 795M | 584M | 464M | |
PRE-TAX INCOME | ||||||||||||||||||||
(112M) | (96M) | (95M) | (84M) | (81M) | (78M) | (74M) | (75M) | (79M) | (72M) | (66M) | (110M) | (107M) | (101M) | (86M) | (96M) | (88M) | (123M) | (91M) | (0.0) | |
-50M | -16M | -44M | -75M | -79M | -70M | -38M | -37M | -57M | -61M | -59M | -101M | -100M | -92M | -72M | -76M | -59M | -10M | 81M | 0.0 | |
(0.0) | (50M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (17M) | (0.0) | (0.0) | (0.0) | -1.2B | -1.1B | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -121M | |
-44M | 33M | -11M | -114M | 13M | -4M | -22M | 42M | -38M | -71M | -42M | -190M | -93M | -76M | -39M | 126M | -40M | 20M | 86M | 163M | |
1.4B | 1.5B | 1.3B | 1.5B | 1.4B | 842M | 919M | 946M | 803M | 544M | 480M | 229M | 293M | 1B | 1B | 692M | 7M | 815M | 670M | 627M | |
NET INCOME | ||||||||||||||||||||
(132M) | (232M) | (99M) | (250M) | (150M) | (123M) | -152M | (630M) | (119M) | (82M) | (42M) | -3M | (68M) | -110M | (20M) | (8M) | (38M) | (122M) | (32M) | (91M) | |
1.3B | 1.3B | 1.2B | 1.3B | 1.2B | 719M | 1.1B | 316M | 684M | 460M | 401M | 549M | 724M | 1.2B | 1B | 684M | -31M | 693M | 638M | 3.3B |
SEC Filings
A - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q2 Q2 | June 01, 2026 | April 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 27, 2026 | May 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | May 04, 2026 | 2026 | |
8-K/A 8-K/A 2026 (Amended) N/A | April 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 03, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 20, 2026 | March 18, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 06, 2026 | March 05, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | March 03, 2026 | January 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 25, 2026 | February 25, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | February 06, 2026 | March 18, 2026 | 2026 |
Related Guides
Continue your A research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.